Innovation

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a COVID-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.

Innovativeness and a commitment to social responsibility are just some of the respected attributes that helped the company land on the prestigious list for another year.

The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world’s second largest outbreak of the disease.

The company just released its inaugural Diversity & Inclusion Impact Review. We take a look inside its pages to see how the company’s striving every day to build a culture of belonging.

As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.

Announced ahead of the International AIDS Society Conference on HIV Science in Mexico City, the new study will evaluate an investigational vaccine regimen in eight countries around the world for its ability to protect people from HIV infection.

Learn about the revolutionary work they’re both doing in the field of neurodegenerative disease that could prove important in fighting often-fatal conditions.

A study of women, by women. We’re talking about the Imbokodo trial, which is evaluating an investigational HIV vaccine in sub-Saharan Africa. As the study hits a key milestone, we sat down with South African physician and scientist Glenda Gray, who’s at the helm of the groundbreaking trial.

Creative recycling initiatives. Global sustainability pledges. Innovative products. In honor of Earth Day, we’re taking a look at how the company is helping to increase recycling, reduce environmental impact and boost sustainability.

A new World Health Organization prequalification for mebendazole means the company can reach even more young people with intestinal worm infections around the globe.